Shulman Joseph 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Oct 30, 2025
Insider Transaction Report
Form 4
Shulman Joseph
Chief Technical Officer
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2025-10-28−721→ 9,748 totalExercise: $30.66Exp: 2031-02-10→ Common Stock (721 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2025-10-28−2,094→ 12,563 totalExercise: $27.35Exp: 2033-01-31→ Common Stock (2,094 underlying) - Exercise/Conversion
Common Stock
2025-10-28$27.35/sh+2,094$57,271→ 10,603 total - Exercise/Conversion
Common Stock
2025-10-28$30.66/sh+721$22,106→ 11,324 total - Sale
Common Stock
2025-10-28$115.01/sh−2,815$323,750→ 8,509 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.00 to $115.08 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F4]The stock option is fully vested.